Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AYESHA S LALL

Allopathic & Osteopathic Physicians Psychiatry & Neurology Child & Adolescent Psychiatry

NPI
1942221031
CMS profile
389680
Location
GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$95.95

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $95.95 6

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $76.61 5
Otsuka America Pharmaceutical, Inc. $19.34 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AYESHA S LALL

NPI 1942221031 · CMS profile ID 389680

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Child & Adolescent Psychiatry

GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942221031?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AYESHA S LALL, NPI 1942221031, CMS profile ID 389680. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942221031?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AYESHA S LALL, NPI 1942221031, CMS profile ID 389680. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942221031?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AYESHA S LALL, NPI 1942221031, CMS profile ID 389680, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1942221031?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $95.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $14.3012/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795207541 CMS
AbbVie Inc. $19.0411/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795207535 CMS
AbbVie Inc. $18.1310/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795207528 CMS
AbbVie Inc. $12.6909/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795207522 CMS
Otsuka America Pharmaceutical, Inc. $19.3407/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834746173 CMS
AbbVie Inc. $12.4506/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795207516 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $197.36 9
PY2020 $21.52 1
PY2021 $95.95 6
PY2022 $791.33 15
PY2023 $2,751.71 6
PY2024 $125.00 1
PY2025 $121.85 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $59,940.10 16
PY2024 Recipient $4,018.01 1
PY2024 Principal investigator $1,034,923.37 95
PY2023 Recipient $433.35 1
PY2023 Principal investigator $392,083.87 69
PY2022 Recipient $300.00 1
PY2022 Principal investigator $934,493.97 37
PY2021 Recipient $50.00 1
PY2021 Principal investigator $735,009.90 45
PY2020 Recipient $1,527.20 10
PY2020 Principal investigator $316,155.93 41
PY2019 Recipient $5,932.16 1
PY2019 Principal investigator $70,452.96 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eisai Inc. $17,355.00 12/01/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648867
Principal investigator 1 Eisai Inc. $13,000.00 12/01/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648873
Principal investigator 1 Biogen, Inc. $437.82 11/12/2021 Non-covered Recipient Entity
Bioclinica Research
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 828999117
Principal investigator 1 Eisai Inc. $13,760.00 10/01/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648855
Principal investigator 1 Eisai Inc. $7,910.00 10/01/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648861
Principal investigator 1 Eli Lilly and Company $13.30 09/24/2021 Non-covered Recipient Entity
ADVENT HEALTH
A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819451397
Principal investigator 1 ABBVIE INC. $100.00 09/09/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792475221
Principal investigator 1 ABBVIE INC. $2,941.65 09/09/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792475223
Principal investigator 1 Eisai Inc. $2,600.00 09/01/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648849
Principal investigator 1 Eli Lilly and Company $187,396.00 08/30/2021 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819454187
Principal investigator 1 ACADIA Pharmaceuticals Inc $618.43 08/20/2021 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
ACP-103-047 No dispute reported 06/30/2026 837697721
Principal investigator 1 Eisai Inc. $32,080.00 08/01/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648839
Principal investigator 1 Eisai Inc. $9,685.00 08/01/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648845
Principal investigator 1 ABBVIE INC. $100.00 07/01/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792466393
Principal investigator 1 Eisai Inc. $34,600.00 07/01/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648827
Principal investigator 1 Eisai Inc. $15,350.00 07/01/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648833
Principal investigator 1 ABBVIE INC. $10,050.00 06/29/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792464429
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,418.85 06/21/2021 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
ACP-103-047 No dispute reported 06/30/2026 837697597
Principal investigator 1 Eisai Inc. $2,600.00 06/10/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648889
Principal investigator 1 Eisai Inc. $2,600.00 06/10/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648895
Recipient Eli Lilly and Company $50.00 05/31/2021 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819443479
Principal investigator 1 Eli Lilly and Company $405.81 05/28/2021 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
DONANEMAB FOLLOW-ON STUDY: SAFETY, TOLERABILITY, AND EFFICACY IN SYMPTOMATIC ALZHEIMER'S DISEASE WITH VALIDATION OF REMOTE NEUROPSYCHOLOGICAL ASSESSMENTS No dispute reported 06/30/2026 819454453
Principal investigator 1 Eli Lilly and Company $128,481.00 05/27/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819455313
Principal investigator 1 Eli Lilly and Company $766.10 05/21/2021 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819454591
Principal investigator 1 Eisai Inc. $3,750.00 05/11/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648879
Principal investigator 1 Eisai Inc. $3,750.00 05/11/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid No dispute reported 06/30/2026 850648885
Principal investigator 1 ABBVIE INC. $300.00 05/10/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792456193
Principal investigator 1 ABBVIE INC. $420.00 05/10/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792456197
Principal investigator 1 ABBVIE INC. $7,084.80 05/10/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792456203
Principal investigator 1 ACADIA Pharmaceuticals Inc $15,967.80 05/07/2021 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
ACP-103-046 No dispute reported 06/30/2026 837697497
Principal investigator 1 Eli Lilly and Company $50.00 04/30/2021 Non-covered Recipient Entity
WAKE RESEARCH ASSOCI
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819467465
Principal investigator 1 Eli Lilly and Company $6,948.98 04/27/2021 Non-covered Recipient Entity
RADIANT RESEARCH INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819466059
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,523.38 04/08/2021 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
ACP-103-047 No dispute reported 06/30/2026 837697427
Principal investigator 1 Eli Lilly and Company $63.25 04/07/2021 Non-covered Recipient Entity
HIGHLANDS ONCOLOGY GROUP PA
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819460211
Principal investigator 1 ABBVIE INC. $9,232.65 03/31/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792440451
Principal investigator 1 ABBVIE INC. $58,351.15 03/11/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792433323
Principal investigator 1 ABBVIE INC. $5,390.00 03/02/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792430403
Principal investigator 1 ABBVIE INC. $11,380.50 03/02/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792430409
Principal investigator 1 ABBVIE INC. $1,541.20 02/19/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
An Extension Study of ABBV-8E12 in Early Alzheimers Disease No dispute reported 06/30/2026 792424789
Principal investigator 1 ABBVIE INC. $690.00 02/10/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792422181
Principal investigator 1 ABBVIE INC. $745.00 02/10/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792422187
Principal investigator 1 ABBVIE INC. $500.00 02/08/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792421507
Principal investigator 1 ABBVIE INC. $11,600.55 01/28/2021 Non-covered Recipient Entity
COMPASS CLINIC LLC
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease No dispute reported 06/30/2026 792416903
Principal investigator 1 Eli Lilly and Company $2,852.68 01/26/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819455185
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $56,989.00 01/21/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 844171843
Principal investigator 1 Biogen, Inc. $47,610.00 01/08/2021 Non-covered Recipient Entity
Bioclinica Research
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease No dispute reported 06/30/2026 829000227